Folotyn for Non-Hodgkin's Lymphoma Cortlandt Manor NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Javier A Ruiz, MD
(845) 561-4450
59 New Windsor Hwy Rte 32
New Windsor, NY
SOMASUNDARAM JAYABOSE, MD
(914) 493-7997
19 Bradhurst Avenue
Hawthorne, NY
Xilian Li, MD
718-670-5534
706 Old Country Rd
Elmsford, NY
Sheryl L Leventha, MS
845-362-1750
500 New Hempstead Rd Ste C
New City, NY
Louise G Ligresti, MD
914-368-3115
36 Oxford Dr
Montebello, NY
Umangi M Patel
(845) 561-6100
611 Gidney Ave
Newburgh, NY
WOONDONG JEONG, MD
(914) 493-8375
19 Bradhurst Avenue
Hawthorne, NY
Roscoe Bruce Guy, MD
718-920-9202
7 Perth Ct
West Nyack, NY
Lawrence Eugene Posner, MD
203-622-0117
633 Round Hill Rd
Greenwich, CT
Andrzej Piotr Kudelka, MD,
713-409-7344
6 Westview Dr
Katonah, NY
Data Provided by:
      

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles